Ruth Ralbag - ICL Israel External Independent Director
ICL Stock | ILA 1,768 5.00 0.28% |
Director
Ms. Ruth Ralbag serves External Independent Director at ICLIsrael Chemicals Ltd. since January 10, 2018. Her work experience includes the following roles Chief Financial Officer of Shaare Zedek Medical Center in Jerusalem, Deputy Director of Medical Finance at the Tel Aviv Sourasky Medical Center, Deputy Director General of Planning, Budget and Pricing at Israel Ministry of Health, Vice President and Head of Commercial and Retail Banking division at FIBI, Acting Chairperson of the Board at FIBI Mortgages Ltd., Acting Chairperson of the Board at Atzmaut Mortgage Bank Ltd. and Director at a variety of additional companies. She holds Directorship in various other companies. She holds a Bachelors degree in Economics and Business Administration and a Masters degree in Public Policy, both from The Hebrew University of Jerusalem. since 2018.
Age | 59 |
Tenure | 6 years |
Phone | (972) 3 684 4427 |
Web | www.icl-group.com |
ICL Israel Management Efficiency
The company has return on total asset (ROA) of 0.1916 % which means that it generated a profit of $0.1916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4322 %, meaning that it generated $0.4322 on every $100 dollars invested by stockholders. ICL Israel's management efficiency ratios could be used to measure how well ICL Israel manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Zeev Vurembrand | Bezeq Israeli Telecommunication | 66 | |
Nir Zichlinskey | Bank Hapoalim | 49 | |
Yosef Yarom | Bank Hapoalim | 73 | |
Or Elovitch | Bezeq Israeli Telecommunication | 40 | |
Shai Hermesh | Bank Leumi Le Israel | 70 | |
Moshe Koren | Bank Hapoalim | 81 | |
Imri Tov | Bank Hapoalim | 76 | |
Yitzhak Sharir | Bank Leumi Le Israel | 66 | |
Nurit Segal | Bank Leumi Le Israel | 72 | |
Perry Nisen | Teva Pharmaceutical Industries | 63 | |
Moshe Many | Teva Pharmaceutical Industries | 85 | |
HajYehia Samer | Bank Leumi Le Israel | 48 | |
Ronit Rokach | Bank Hapoalim | 61 | |
Mali Baron | Bank Hapoalim | 66 | |
Tali Simon | Bezeq Israeli Telecommunication | 48 | |
Gabrielle Sulzberger | Teva Pharmaceutical Industries | 56 | |
Galia Maor | Teva Pharmaceutical Industries | 73 | |
Irit Izakson | Bank Hapoalim | 63 | |
Amnon Dick | Bank Hapoalim | 63 | |
Moshe Dovrat | Bank Leumi Le Israel | 69 | |
Shlomo Rodav | Bezeq Israeli Telecommunication | 67 |
Management Performance
Return On Equity | 0.43 | |||
Return On Asset | 0.19 |
ICL Israel Chemicals Leadership Team
Elected by the shareholders, the ICL Israel's board of directors comprises two types of representatives: ICL Israel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ICL. The board's role is to monitor ICL Israel's management team and ensure that shareholders' interests are well served. ICL Israel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ICL Israel's outside directors are responsible for providing unbiased perspectives on the board's policies.
Nitzan Moshe, Executive Vice President - Global Operations | ||
Ronnie Shushan, Senior Vice President - Investments & Projects | ||
Tzipi OzerArmon, Independent Director | ||
Ilana Fahima, Executive Vice President ICL Global Human Resources | ||
Amir Benita, Vice President of Accounting | ||
Nir Gilad, Chairman of the Board | ||
Ruth Ralbag, External Independent Director | ||
Noam Goldstein, President - Potash Division | ||
Dan Chen, Executive VP of Corporate Relations and Deputy CEO of Foreign Relations | ||
Stefan Borgas, CEO and President and Director | ||
Anantha Desikan, Executive Vice President Chief Innovation & Technology Officer | ||
Charles Weidhas, CEO of ICL Industrial Products and President of ICL Industrial Products | ||
Eli Glazer, President of ICL´s Phosphate Solutions Division | ||
Osi Sessler, Vice President of Investor Relations and Communications | ||
Karl Mielke, Executive Vice President-Specialty Fertilizers | ||
Lizette Killian, Senior Vice President-Global Corporate Relations | ||
Aya Landman, Company VP | ||
Ofer Lifshitz, President, ICL Phosphate Solutions Division | ||
Eran Sarig, Director | ||
Anat TalKtalav, President ICL Industrial Products Division | ||
Michael Hazzan, Vice President - Finance | ||
Geoffery Merszei, Director | ||
Asher Grinbaum, Deputy CEO, COO, Chief Risk Officer and Executive VP | ||
Advocate GevaHarel, Exec Counsel | ||
Eli Amit, Senior Vice President-Economics | ||
Israel Dreyfuss, Controller | ||
Yaacov Dior, External Director | ||
Raviv Zoller, Chief Executive Officer | ||
Johanan Locker, Executive Chairman of the Board | ||
Lilach GevaHarel, Senior Vice President and Global General Counsel | ||
Rani Loebenstein, Senior Vice President-Corporate Relations | ||
Shimon Eckhaus, Director | ||
Avisar Paz, Director | ||
Yoav Doppelt, Executive Chairman of the Board | ||
Mark Volmer, CEO of the Performance Products segment | ||
Ido Lilian, Executive Vice President-Global Procurement | ||
Hezi Israel, Vice President Business Development and Strategy | ||
Reem Aminoach, Independent Director | ||
Nissim Adar, CEO of ICL Fertilizers and President of ICL Fertilizers | ||
Maya Grinfeld, VP Communications | ||
Lisa Haimovitz, Deputy CEO, General Counsel, Secretary | ||
Aviram Lahav, Chief Officer | ||
Ron Moskovitz, Director | ||
Lior Reitblatt, Independent Director | ||
Nadav Kaplan, Independent Director | ||
Herzel Niv, Vice President of International Taxation | ||
Kobi Altman, CFO, Executive Vice President | ||
Lilach Harel, Senior Vice President and Global General Counsel | ||
Eli Amon, Executive Vice President ICL Innovative Ag Solutions Division | ||
Aviad Kaufman, Director | ||
Miri Mishor, Senior Vice President - ICL Global Information Technology | ||
Shmuel Daniel, Internal Auditor | ||
Ovadia Eli, External Director | ||
Amir Meshulam, Senior Vice President Global Internal Auditor | ||
Eyal Ginzberg, CTO | ||
Elad Aharonson, Pres Solutions | ||
Yakir Menashe, Senior Vice President-Global Human Resources | ||
Miriam Haran, External Director | ||
Sagi Kabla, Director |
ICL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ICL Israel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.43 | |||
Return On Asset | 0.19 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 0.34 % | |||
Current Valuation | 43.75 B | |||
Shares Outstanding | 1.29 B | |||
Shares Owned By Insiders | 44.90 % | |||
Shares Owned By Institutions | 25.12 % | |||
Price To Book | 2.00 X | |||
Price To Sales | 3.31 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ICL Israel Chemicals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for ICL Stock analysis
When running ICL Israel's price analysis, check to measure ICL Israel's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ICL Israel is operating at the current time. Most of ICL Israel's value examination focuses on studying past and present price action to predict the probability of ICL Israel's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ICL Israel's price. Additionally, you may evaluate how the addition of ICL Israel to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
CEOs Directory Screen CEOs from public companies around the world | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |